Blue Earth Diagnostics
Quick facts
Marketed products
- Flotufolastat (18F) · Oncology
Flotufolastat (18F) is a fluorine-18 labeled folate analog that binds to folate receptors on cancer cells for positron emission tomography (PET) imaging. - piflufolastat (18F) · Oncology
Piflufolastat (18F) is a fluorine-18 labeled small molecule that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.
Phase 3 pipeline
- rhPSMA-7.3 (18F) Injection · Oncology
rhPSMA-7.3 (18F) Injection is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Blue Earth Diagnostics
What are Blue Earth Diagnostics's marketed drugs?
Top marketed products include Flotufolastat (18F), piflufolastat (18F).
What is Blue Earth Diagnostics's pipeline?
Blue Earth Diagnostics has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include rhPSMA-7.3 (18F) Injection.
Related
- Flotufolastat (18F) · Oncology
- piflufolastat (18F) · Oncology
- Sector hub: All tracked pharma companies